Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Tuesday 25 September, 2007

XTL Biopharm Ltd

XTL AGM / EGM POSTPONED UNTIL OCTOBER 2, 2007


     XTL BIOPHARMACEUTICALS LTD. AGM / EGM POSTPONED UNTIL OCTOBER 2, 2007     

Valley Cottage, New York, September 25, 2007 - XTL Biopharmaceuticals Ltd.
(NASDAQ: XTLB; LSE: XTL; TASE: XTL) announces today that its Annual General
Meeting ("AGM") and Extraordinary General Meeting ("EGM") was postponed for one
week in accordance with its articles of association due to the absence of a
quorum. The postponed AGM and EGM will take place at the Company, Building 3,
Kiryat Weizmann Science Park, Rehovot, Israel 76100 at 4:00 pm and 4:30pm,
respectively on October 2, 2007.

Any proxy votes received at any time up to 48 hours prior to the postponed AGM
and EGM will be included in the total votes counted for the AGM and EGM. Those
shareholders who have a valid "proof of ownership" in Israel or a letter of
representation from Computershare, the Company's registrars, and attend the
meeting in person will also be permitted to vote.

As a result of postponing the EGM, the Company anticipates that the time and
date for the cancellation of the listing of its Ordinary Shares from the
Official List of the United Kingdom Listing Authority, being not less than 20
business days from the date of the EGM as required by the United Kingdom
Listing Rules, is now 8:00 am (London Time) on October 31, 2007.

ABOUT XTL BIOPHARMACEUTICALS LTD.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of
therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is
developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for
the treatment of diabetic neuropathic pain. XTL is also developing several
novel pre-clinical hepatitis C small molecule inhibitors. XTL also has an
active in-licensing and acquisition program designed to identify and acquire
additional drug candidates. XTL is publicly traded on the NASDAQ, London, and
Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

Contact:

Ron Bentsur, Chief Executive Officer

Tel: +1-(845)-267-0707 ext. 225

                                                                               
                                  Page 2 of 1                                  


                                                                                    

a d v e r t i s e m e n t